Which stocks to buy, hold or sell today? As Dalal Street enters the May 19 session, here's a look at what brokerages make of some of the key stocks in focus.

COMMERCIAL BREAK
SCROLL TO CONTINUE READING

State Bank of India (SBI), ITC, Granules, InterGlobe Aviation (IndiGo), ConCor, Zydus Lifescience, Gland Pharma, Tata Elxsi, and other stocks are on their radar today.

Do you have any of these stocks in your portfolio?

State Bank of India (SBI)

Most brokerages are bullish on State Bank of India shares after India’s largest lender announced higher-than-estimated earnings for the March quarter of FY23 on Thursday.

CLSA, Jefferies, Goldman Sachs, and Citi each have a ‘buy’ rating, while Morgan Stanley and JP Morgan each maintained an ‘overweight’ stance on the stock.

Brokerage Rating Price Target
CLSA Buy Rs 725
Morgan Stanley Overweight Rs 715
JP Morgan Overweight Rs 720
Jefferies Buy Rs 760
Goldman Sachs Buy Rs 746
Citi Buy Rs 710
Macquarie Outperform Rs 695

ITC Limited

Amid registering strong Q4 earnings, most brokerages such as Citi, Jefferies, Nomura, and Goldman Sachs have a ‘buy’ rating on the ITC shares. The cigarette-to-hotels conglomerate on Thursday announced higher-than-expectations numbers in the March quarter of FY23.

Brokerage Rating Price Target
Morgan Stanley Overweight Rs 474
JP Morgan Overweight Rs 425
Citi Buy Rs 480
Jefferies buy Rs 520
Nomura Buy Rs 485
Goldman Sachs Buy Rs 470

InterGlobe Aviation (IndiGo)

On the back of better performance in Q4 earnings, the majority of the global brokerages are upbeat on IndiGo shares as JP Morgan and Morgan Stanley each retained an ‘overweight’ rating. At the same time, Citi and Goldman Sachs have a ‘buy’ call on the aviation stock.

Brokerage Rating Price Target
JP Morgan Overweight Rs 2,700
Morgan Stanley Overweight Rs 3,126
Citi Buy Rs 2,400
Jefferies Underperform Rs 1,950
Credit Suisse Outperform Rs 2,450
Goldman Sachs Buy Rs 2,600

ConCor

Brokerages are divided on Container Corporation – a state-run company – after the government-owned firm’s margins for the quarter came below estimate. Morgan Stanley has an ‘equal weight’, Macquarie ‘underperform’ and Nomura ‘neutral’ rating on the stock.

Brokerage Rating Price Target
Morgan Stanley Equal weight Rs 660
Macquarie Underperform Rs 620
Nomura Neutral Rs 635

Zydus Lifescience

Brokerage Rating Price Target
Morgan Stanley Overweight Rs 646
Jefferies Buy Rs 585
Nomura Buy Rs 540
Macquarie Underperform Rs 400

GAIL India

Brokerage Rating Price Target
Morgan Stanley Overweight Rs 135
Citi Buy Rs 125
Jefferies Hold Rs 110
Macquarie Outperform Rs 140

Gland Pharma

 

Brokerage Rating Price Target
Goldman Sachs Buy Rs 1,475
Citi Sell Rs 925
Jefferies Underperform Rs 1,065

 

Catch the latest stock market updates here. For all other news related to business, politics, tech, sports and auto, visit Zeebiz.com.